News

Cold agglutinin disease (CAD) is more frequently diagnosed during winter months at multiple locations across Europe, supporting outdoor temperature as a disease trigger, researchers reported. Findings also suggest that, in general, people living in places with milder weather may be less likely to experience CAD symptoms and, as such,…

A pregnant woman with a rare case of tuberculosis-induced cold autoimmune hemolytic anemia — also known as cold agglutinin disease (CAD) — was successfully treated with plasma exchange and medications for her tuberculosis.  According to its authors, this “favorable…

More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports. These findings…

A woman developed cold agglutinin disease (CAD) and myositis (muscle inflammation) as a complication of COVID-19, underscoring the importance of a timely, comprehensive evaluation to identify rare complications of SARS-CoV-2 infection. Researchers noted that the patient’s…

The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a rare disease pursue personal goals through training and education. For a second year, the #RAREis Scholarship Fund — supported by Horizon Therapeutics – will award 35 one-time scholarships, each…

Sanofi’s investigational therapy sutimlimab safely and rapidly prevents red blood cell destruction (hemolysis), increases hemoglobin levels, and reduces fatigue in adults with primary cold agglutinin disease (CAD), according to full data from Part A of the Phase 3 CARDINAL study. These therapeutic benefits were associated with a fast and…

As anyone affected by a rare disease knows, treating the illness while trying to go about everyday life is an expensive undertaking.  But exactly how expensive — in terms of direct and indirect costs across rare disease populations — might still come as a surprise: almost…

Daratumumab eased circulatory symptoms and anemia without causing adverse side effects in a 59-year-old man with cold agglutinin disease (CAD), a recent medical case study reported. The antibody-based medication, normally used to treat myeloma, may offer an alternative to CAD patients who fail to respond to other therapies,…

The case of a man with COVID-19 who temporarily developed elevated levels of cold agglutinins — the self-reactive antibodies that cause cold agglutinin disease (CAD) — was described in a recent report. According to researchers, this is the third known case of elevated cold agglutinin levels documented in…

Physicians should be aware that patients with autoimmune hemolytic anemia (AIHA) are at greater risk of experiencing thrombotic events — blood vessel obstruction driven by blood clots — to better manage their condition, a case report highlighted. The case study, “Autoimmune Hemolytic…